- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07489495
En klinisk undersøgelse af Belzutifan (MK-6482) og Zanzalintinib hos personer med nyrecellekarcinom (RCC) (LITESPARK-034/LS-034/MK-6482-034)
En fase 3, randomiseret, dobbeltblind undersøgelse af Belzutifan + Zanzalintinib versus Belzutifan + Placebo hos deltagere med avanceret RCC, der har haft progression under eller efter både PD-1/L1- og VEGF-TKI-behandlinger i sekvens eller i kombination (LITESPARK-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).
A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studiesteder
-
-
-
CABA, Argentina, C1426ANZ
- Rekruttering
- Instituto Alexander Fleming ( Site 0252)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +541132218900
-
La Rioja, Argentina, X5004BAL
- Rekruttering
- Centro Oncológico Riojano Integral ( Site 0256)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +543804436443X108
-
San Juan, Argentina, J5402BGA
- Rekruttering
- COE (Centro Oncológico de Excelencia) ( Site 0259)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +54 2644229585
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, C1426AHB
- Rekruttering
- Centro Oncologico Korben ( Site 0254)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +541159507952
-
Ciudad de Buenos Aires, Buenos Aires, Argentina, 1181
- Rekruttering
- Hospital Italiano de Buenos Aires ( Site 0253)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +541149590200
-
Mar del Plata, Buenos Aires, Argentina, B7600FZO
- Rekruttering
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +542234963224
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentina, X5800ALB
- Rekruttering
- Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +543584620273
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DSV
- Rekruttering
- Sanatorio Parque ( Site 0251)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5493416955611
-
Rosario, Santa Fe Province, Argentina, S2000KZE
- Rekruttering
- Instituto de Oncología de Rosario ( Site 0257)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +543414484830
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, Australien, 2109
- Suspenderet
- Macquarie University ( Site 2700)
-
-
Queensland
-
Woolloongabba, Queensland, Australien, 4102
- Suspenderet
- Princess Alexandra Hospital ( Site 2703)
-
-
Victoria
-
Melbourne, Victoria, Australien, 3000
- Suspenderet
- Peter MacCallum Cancer Centre ( Site 2702)
-
-
Western Australia
-
Murdoch, Western Australia, Australien, 6150
- Suspenderet
- Fiona Stanley Hospital ( Site 2704)
-
-
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brasilien, 29055-450
- Rekruttering
- CEDOES ( Site 0303)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +552721250202
-
-
Paraná
-
Curitiba, Paraná, Brasilien, 80510-130
- Rekruttering
- Instituto do Câncer e Transplante de Curitiba ( Site 0300)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +55 41 99205-7755
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasilien, 59062-000
- Rekruttering
- Liga Norte Riograndense Contra o Câncer ( Site 0307)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +55 84 4009-5595
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brasilien, 14026-610
- Rekruttering
- Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +55 16 3913-8181
-
São José do Rio Preto, São Paulo, Brasilien, 15090-000
- Rekruttering
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +55 17 3201-5054
-
-
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Rekruttering
- The Ottawa Hospital Cancer Centre ( Site 0003)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 613-737-7700
-
-
Quebec
-
Québec, Quebec, Canada, G1J 1Z4
- Rekruttering
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 418-525-4444
-
-
-
-
Coquimbo Region
-
La Serena, Coquimbo Region, Chile, 1720430
- Rekruttering
- IC La Serena Research ( Site 0405)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 56958646664
-
-
Los Lagos Region
-
Port Montt, Los Lagos Region, Chile, 5500243
- Rekruttering
- Clínica Puerto Montt ( Site 0404)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56985383586
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 7500921
- Rekruttering
- Fundacion Arturo Lopez Perez ( Site 0401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 56224205098
-
Santiago, Region M. de Santiago, Chile, 8420383
- Rekruttering
- Bradfordhill ( Site 0400)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 56229490970
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Rekruttering
- ONCOCENTRO APYS ( Site 0403)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 56323320850
-
-
-
-
Capital Region
-
Herlev, Capital Region, Danmark, 2730
- Rekruttering
- Herlev Hospital ( Site 1002)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 00 45 38689191
-
-
Central Jutland
-
Aarhus, Central Jutland, Danmark, 8200
- Rekruttering
- Aarhus Universitetshospital, Skejby ( Site 1001)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4591167472
-
-
Region Syddanmark
-
Odense, Region Syddanmark, Danmark, 5000
- Rekruttering
- Odense Universitets Hospital ( Site 1000)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4566113333
-
-
-
-
-
Birmingham, Det Forenede Kongerige, B15 2GW
- Rekruttering
- University Hospitals Birmingham NHS Foundation Trust ( Site 2610)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4407789651543
-
Cardiff, Det Forenede Kongerige, CF14 2TL
- Rekruttering
- Velindre Cancer Centre ( Site 2612)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +442920615888
-
Southampton, Det Forenede Kongerige, SO16 6YD
- Rekruttering
- University Hospital of Southampton ( Site 2606)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 023 8077 7222
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Det Forenede Kongerige, CB2 0QQ
- Rekruttering
- Addenbrookes Hospital ( Site 2605)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +441223805000
-
-
Edinburgh, City of
-
Edinburgh, Edinburgh, City of, Det Forenede Kongerige, EH4 2XU
- Rekruttering
- Western General Hospital ( Site 2608)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +441315371398
-
-
Glasgow City
-
Glasgow, Glasgow City, Det Forenede Kongerige, G12 0YN
- Rekruttering
- The Beatson West of Scotland Cancer Centre ( Site 2602)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +441413019916
-
-
Leicestershire
-
Leicester, Leicestershire, Det Forenede Kongerige, LE1 5WW
- Rekruttering
- Leicester Royal Infirmary ( Site 2604)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0300 303 1573
-
-
London, City of
-
Northwood, London, City of, Det Forenede Kongerige, HA6 2RN
- Rekruttering
- Mount Vernon Hospital ( Site 2607)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4401923826111
-
-
Manchester
-
Withington, Manchester, Det Forenede Kongerige, M20 4BX
- Rekruttering
- The Christie Hospital NHS Foundation Trust ( Site 2601)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0161 918 2546
-
-
-
-
California
-
Duarte, California, Forenede Stater, 91010
- Rekruttering
- City of Hope Comprehensive Cancer Center ( Site 0129)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 877-817-9982
-
Irvine, California, Forenede Stater, 92618
- Rekruttering
- City of Hope Lennar Foundation Cancer Center ( Site 0142)
-
Kontakt:
- Study Coordinator
- Telefonnummer: see site 0129
-
-
Georgia
-
Marietta, Georgia, Forenede Stater, 30060
- Rekruttering
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 770-281-5124
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- Rekruttering
- University of Louisville, James Graham Brown Cancer Center ( Site 0133)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 502-562-4673
-
Louisville, Kentucky, Forenede Stater, 40207
- Rekruttering
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0104)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 502-899-3366
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Beth Israel Deaconess Medical Center ( Site 0139)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 617-667-7000
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana Farber Cancer Institute ( Site 0135)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 617-632-3000
-
-
Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Rekruttering
- The Cancer and Hematology Centers ( Site 0123)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 616-954-9800
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University School of Medicine ( Site 0114)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 314-362-7355
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0108)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 551-996-5900
-
Morristown, New Jersey, Forenede Stater, 07960
- Rekruttering
- Atlantic Health System Morristown Medical Center ( Site 0109)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 973-971-7960
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center ( Site 0126)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 347-798-9213
-
-
Tennessee
-
Germantown, Tennessee, Forenede Stater, 38138
- Rekruttering
- The West Clinic, P.C. ( Site 0115)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 901-683-0055
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390
- Rekruttering
- UT Southwestern Medical Center ( Site 0119)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 214-648-3111
-
-
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Frankrig, 06189
- Rekruttering
- Centre Antoine Lacassagne ( Site 1209)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33492031538
-
-
Bouches-du-Rhone
-
Marseille, Bouches-du-Rhone, Frankrig, 13003
- Rekruttering
- Hopital Europeen Marseille ( Site 1216)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33413427427
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, Frankrig, 31059
- Rekruttering
- LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1215)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33531155050
-
-
Maine-et-Loire
-
Angers, Maine-et-Loire, Frankrig, 49933
- Rekruttering
- CHU Angers ( Site 1204)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33241354694
-
-
Pays de la Loire Region
-
Le Mans, Pays de la Loire Region, Frankrig, 72000
- Rekruttering
- Clinique Victor Hugo Le Mans-Oncology-Radiotherapy ( Site 1203)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33 243297908
-
Saint Priest En Jarez, Pays de la Loire Region, Frankrig, 42271
- Rekruttering
- CHU de Saint-Etienne ( Site 1202)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33477917082
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, Frankrig, 94800
- Rekruttering
- Gustave Roussy ( Site 1214)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33142114211
-
-
-
-
Attica
-
Athens, Attica, Grækenland, 185 47
- Rekruttering
- Metropolitan Hospital ( Site 1402)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +302104809667
-
Athens, Attica, Grækenland, 124 62
- Rekruttering
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +302105832549
-
Athens, Attica, Grækenland, 115 28
- Rekruttering
- Alexandra General Hospital of Athens ( Site 1400)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +302132162543
-
-
-
-
Limburg
-
Maastricht, Limburg, Holland, 6229 HX
- Rekruttering
- Maastricht UMC+ ( Site 1901)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +31433877025
-
-
North Holland
-
Amsterdam, North Holland, Holland, 1066 CX
- Rekruttering
- Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +3120 512 9111
-
-
South Holland
-
Schiedam, South Holland, Holland, 3118 JH
- Rekruttering
- Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1903)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +31108931441
-
The Hague, South Holland, Holland, 2545 AA
- Rekruttering
- Haga Ziekenhuis locatie Leyweg ( Site 1906)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +3170 210 2143
-
-
-
-
-
Haifa, Israel, 3109601
- Rekruttering
- Rambam Health Care Campus ( Site 1600)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +97247772688
-
Kfar Saba, Israel, 4428164
- Rekruttering
- Meir Medical Center. ( Site 1603)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +97297472555
-
Petah Tikva, Israel, 4941492
- Rekruttering
- Rabin Medical Center ( Site 1602)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 97239378074
-
Ramat Gan, Israel, 5265601
- Rekruttering
- Sheba Medical Center ( Site 1601)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 97235303030
-
-
-
-
-
Bari, Italien, 70124
- Rekruttering
- Azienda Ospedaliera Policlinico di Bari ( Site 1802)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 00390805593767
-
Bologna, Italien, 40138
- Rekruttering
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1803)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390512142204
-
Milan, Italien, 20133
- Rekruttering
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1800)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 02 2390 3028
-
Perugia, Italien, 06132
- Rekruttering
- AO Santa Maria della Misericordia ( Site 1805)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +39 0755784188
-
Roma, Italien, 00168
- Rekruttering
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 00390630155202
-
Roma, Italien, 00144
- Rekruttering
- Istituto Nazionale Tumori Regina Elena ( Site 1804)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +39 0652666919
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italien, 47014
- Rekruttering
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1809)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390543739100
-
-
Milano
-
Rozzano, Milano, Italien, 20089
- Rekruttering
- Istituto Clinico Humanitas ( Site 1808)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0282244061
-
-
Treviso
-
Castelfranco Veneto, Treviso, Italien, 31033
- Rekruttering
- Istituto Oncologico Veneto IRCCS ( Site 1806)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +39 0423732336
-
-
Tuscany
-
Florence, Tuscany, Italien, 50134
- Rekruttering
- Azienda Ospedaliera Universitaria Careggi ( Site 1807)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390557949648
-
-
-
-
Greater Poland Voivodeship
-
Skórzewo, Greater Poland Voivodeship, Polen, 60-185
- Rekruttering
- AIDPORT Sp. z o.o. ( Site 2118)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +48570783100
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-727
- Rekruttering
- Pratia MCM Krakow ( Site 2115)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +48122958160
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polen, 08-110
- Rekruttering
- Mazowiecki Szpital Wojewódzki im. Sw. Jana Pawla II w Siedlcach Sp. z o.o. ( Site 2102)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +48256403300
-
Warsaw, Masovian Voivodeship, Polen, 02-172
- Rekruttering
- MTZ Clinical Research Powered by Pratia ( Site 2107)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +48225725959
-
Warsaw, Masovian Voivodeship, Polen, 02-781
- Rekruttering
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 2100)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +48225462331
-
-
Silesian Voivodeship
-
Gliwice, Silesian Voivodeship, Polen, 44-102
- Rekruttering
- Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2106)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +48322788237
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekruttering
- Hospital Universitari Vall d Hebron ( Site 2303)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34934894350
-
Las Palmas, Spanien, 35016
- Rekruttering
- Hospital Insular de Gran Canaria ( Site 2308)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34928441738
-
Madrid, Spanien, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre ( Site 2300)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34913908339
-
Valencia, Spanien, 46009
- Rekruttering
- Fundación Instituto Valenciano de Oncología ( Site 2307)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34961114229
-
-
Andalusia
-
Seville, Andalusia, Spanien, 41013
- Rekruttering
- Hospital Universitario Virgen del Rocio ( Site 2306)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34955013068
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spanien, 08908
- Rekruttering
- Institut Català d'Oncologia - L'Hospitalet ( Site 2305)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34932607744
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanien, 28007
- Rekruttering
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34914269393
-
-
-
-
-
Seoul, Sydkorea, 05505
- Rekruttering
- Asan Medical Center ( Site 2901)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +82-2-3010-5977
-
Seoul, Sydkorea, 06351
- Rekruttering
- Samsung Medical Center ( Site 2902)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +82-2-3410-1767
-
Seoul, Sydkorea, 03722
- Rekruttering
- Severance Hospital, Yonsei University Health System ( Site 2903)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +82-2-2228-8138
-
-
-
-
-
Hradec Králové, Tjekkiet, 500 05
- Rekruttering
- Fakultni nemocnice Hradec Kralove ( Site 0902)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +420727854666
-
Olomouc, Tjekkiet, 779 00
- Rekruttering
- Fakultni nemocnice Olomouc ( Site 0901)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +420588445923
-
Prague, Tjekkiet, 150 06
- Rekruttering
- Fakultni nemocnice v Motole ( Site 0900)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +420734236410
-
Prague, Tjekkiet, 128 08
- Rekruttering
- Fakulti poliklinika ( Site 0906)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +420224966405
-
-
Brno-mesto
-
Brno, Brno-mesto, Tjekkiet, 656 53
- Rekruttering
- Masarykuv onkologicky ustav ( Site 0903)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +420543132216
-
-
Ostrava Mesto
-
Ostrava, Ostrava Mesto, Tjekkiet, 708 52
- Rekruttering
- Fakultni nemocnice Ostrava ( Site 0904)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +420597374322
-
-
-
-
-
Adana, Tyrkiet (Türkiye), 01140
- Rekruttering
- Adana Medical Park Seyhan Hastanesi ( Site 2505)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905372688986
-
Ankara, Tyrkiet (Türkiye), 06620
- Rekruttering
- Ankara University Health Practice and Research Hospitals ( Site 2506)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +90 312 595 71 12
-
Edirne, Tyrkiet (Türkiye), 22030
- Rekruttering
- Trakya University Medical Faculty Hospital ( Site 2502)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +9005378528123
-
Istanbul, Tyrkiet (Türkiye), 34010
- Rekruttering
- Koc Universitesi Hastanesi ( Site 2501)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0090 850 250 8 250
-
Izmir, Tyrkiet (Türkiye), 35080
- Rekruttering
- Ege Universitesi Hastanesi ( Site 2503)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0 232 343 43 43
-
-
Ankara
-
Sıhhiye, Ankara, Tyrkiet (Türkiye), 06230
- Rekruttering
- Hacettepe Universite Hastaneleri ( Site 2500)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905439340493
-
-
-
-
-
Berlin, Tyskland, 10117
- Rekruttering
- Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1312)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4930450515288
-
-
Bavaria
-
Augsburg, Bavaria, Tyskland, 86156
- Rekruttering
- Universitaetsklinikum Augsburg ( Site 1316)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +498214002348
-
Munich, Bavaria, Tyskland, 81675
- Rekruttering
- klinikum rechts der isar der technischen universität münchen ( Site 1315)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 00498941402522
-
-
Thuringia
-
Jena, Thuringia, Tyskland, 07747
- Rekruttering
- Universitätsklinikum Jena ( Site 1313)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4936419329970
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a histologically confirmed diagnosis of unresectable, advanced renal cell carcinoma (RCC) with clear cell component (with or without sarcomatoid features) ie, Stage IV RCC per American Joint Committee on Cancer (8th Edition)
- Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
- Has received no more than 3 prior systemic regimens for RCC, including only 1 prior anti-Programmed Cell Death-1/Programmed Cell Death 1 Ligand 1 therapy
Exclusion Criteria:
For exclusion criteria: The main exclusion criteria include but are not limited to the following:
- Has any of the following: a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or required chronic supplemental oxygen
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
- Has deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
- Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
- Has had major surgery within 8 weeks before randomization
- Has current pneumonitis/interstitial lung disease
- Has a history of human immunodeficiency virus infection
- Has Hepatitis B or Hepatitis C virus infection
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has a history of solid organ transplant
- Has not adequately recovered from major surgery or has ongoing surgical complications
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Belzutifan + Zanzalintinib
Participants will receive 120 mg belzutifan orally and 60 mg zanzalintinib once daily for approximately 24 months. |
Tablet for oral administration.
Andre navne:
Tablet for oral administration.
Andre navne:
|
|
Aktiv komparator: Belzutifan + Placebo
Participants will receive 120 mg belzutifan orally and zanzalintinib-matching placebo once daily for approximately 24 months. |
Tablet for oral administration.
Andre navne:
Zanzalintinib-matching placebo tablet for oral administration. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival (PFS)
Tidsramme: Up to approximately 30 months
|
PFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. |
Up to approximately 30 months
|
|
Overall Survival (OS)
Tidsramme: Up to approximately 50 months
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 50 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR)
Tidsramme: Up to approximately 30 months
|
ORR is defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR. |
Up to approximately 30 months
|
|
Duration of Response (DOR)
Tidsramme: Up to approximately 30 months
|
DOR is defined as the interval from the first documented evidence of a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 until Progressive Disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating a best confirmed response of CR or PR. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. |
Up to approximately 30 months
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Tidsramme: Up to approximately 25 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported. |
Up to approximately 25 months
|
|
Number of Participants who Discontinue Study Treatment Due to an AE
Tidsramme: Up to approximately 24 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 24 months
|
|
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Tidsramme: Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Tidsramme: Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Tidsramme: Baseline and up to approximately 25 months
|
The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be reported. |
Baseline and up to approximately 25 months
|
|
Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) (Items 1-9) Score
Tidsramme: Baseline and up to approximately 25 months
|
The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. |
Baseline and up to approximately 25 months
|
|
Time to Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Tidsramme: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
Tidsramme: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score
Tidsramme: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in role functioning (Items 6 and 7). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in Disease Symptoms Using the FKSI-DRS (Items 1-9) Score
Tidsramme: Up to approximately 25 months
|
TTD is defined as time from the first dose of study treatment to the date of deterioration of FKSI-DRS score. The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration is defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration is the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Medical Director, Merck Sharp & Dohme LLC
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Urologiske neoplasmer
- Karcinom
- Nyre-neoplasmer
- Karcinom, nyrecelle
- Belzutifan
Andre undersøgelses-id-numre
- 6482-034
- U1111-1311-4692 (Registry Identifier: UTN)
- 2024-516993-31-00 (Registry Identifier: EU CT)
- LITESPARK-034 (Anden identifikator: MSD)
- MK-6482-034 (Anden identifikator: MSD)
- LS-034 (Anden identifikator: MSD)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .